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ABSTRACT
The proliferating cell nuclear antigen (PCNA) is an
adenovirus E1A-inducible factor that is intimately
linked to the processes of DNA replication and cell
cycle regulation. Previously, we defined a novel
c/s-acting element, the PCNA E1 A-responsive element
(PERE), that confers induction by the E1A 243R
oncoprotein upon the human PCNA promoter. To
better understand the regulation of PCNA expression
by E1A 243R, we have identified cellular transcription
factors that associate with the PERE. In electrophoret-
ic mobility shift assays, the PERE formed three major
complexes (P1, P2 and P3) with proteins in nuclear
extracts from HeLa or 293 cells. Formation of com-
plexes P2 and P3, which correlates with PCNA promoter
activity in vivo, requires the activating transcription
factor (ATF) binding site found within the PERE [Labrie
ef a/. (1993) Mol. Cell. Biol., 13, 1697-1707]. Antibody
interference experiments and mobility shift assays
performed with in w'fro-synthesized protein indicated
that the transcription factor ATF-1 is a major component
of these complexes. Similar assays demonstrated that
the hepatitis B virus enhancer-associated protein RFX1
constitutes a major component of the P1 complex. In
addition, we examined the binding of proteins to the
minimal E1 A-responsive promoter to identify other
factors important for transcription from the PCNA
promoter. Mobility shift assays revealed that a fragment
encompassing the region from -87 to +62 relative to the
transcription initiation site forms at least five com-
plexes, EH1-EH5, with HeLa cell nuclear extracts. The
transcription factor YY1 associates with the initiator
element of the PCNA promoter. The identification of
these transcription factors will allow their roles in the
activation of PCNA by E1A to be evaluated.
INTRODUCTION
The proliferating cell nuclear antigen (PCNA) is a critical
component of the eukaryotic DNA replication and repair
machinery. In vivo, PCNA is required for cell cycle progression
and growth of both yeast and mammalian cells (1) and PCNA
antisense oligonucleotides inhibit BALB/c3T3 cell proliferation
(2). Human PCNA was originally identified as a protein of
-35 000 kDa through its reaction with autoantibodies (3). It is
found as a trimer which appears to be the antigenic as well as the
catalytically active form (4). Proliferating cell nuclear antigen
probably functions as a 'sliding clamp' to increase the processiv-
ity of DNA synthesis (5). As the auxiliary factor of DNA 8 (6,7),
PCNA is involved in the repair of mutagen-damaged DNA (8)
and is required for both leading- and lagging-strand DNA
synthesis in vitro (9,10).
Proliferating cell nuclear antigen activity appears to be regulated
through interactions with cell-cycle regulatory proteins. In normal
diploid fibroblasts, but not in their SV40 virus-transformed
derivatives or other transformed cell lines, PCNA exists in
quaternary complexes containing a cyclin, a cyclin-dependent
kinase (CDK) and the CDK-inhibitor p21 (11-14). More recently,
p21 was shown to inhibit reconstituted SV40 DNA replication
through a direct interaction with PCNA (15). The effect of p21 on
DNA replication in this system was reversed by the addition of
excess PCNA, suggesting that the level of PCNA expression in
transformed cells might play a determining role in the disruption
of normal cell-cycle control of DNA replication.
In this respect, the activation of PCNA expression by
adenovirus is a particularly interesting model for the study of the
molecular mechanisms underlying transformation. The induction
of PCNA by adenovirus El A was first described in rodent cells
(16) and has since been studied in greater detail using transient
expression experiments in HeLa cells (17). Proliferating cell
nuclear antigen induction depends on the transforming functions
of El A common to the 243- and 289-amino acid products of the
adenovirus E1A gene, hereafter referred to as E1A 243 R and E1A
289R, since both are equally capable of inducing PCNA
expression in the context of a viral infection or in transient
expression assays (16,18). More specifically, optimal PCNA
induction requires domains of El A 243R involved in binding to
the transcriptional adaptor p300 (19-21) and the retinoblastoma
protein-related pl07-tumor suppressor protein (20,22).
Activation of PCNA expression by El A occurs at the
transcriptional level through an increase in PCNA promoter
activity (18). A PCNA El A-responsive element, termed the
PERE, resides between -59 and -45 relative to the transcription
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start site of the human PCNA promoter and contains a sequence
from -52 to -45 which is homologous to an activating transcrip-
tion factor (ATF) motif (23). The PERE is required for basal and
El A 243R-induced PCNA expression in transient expression
assays (23) and can confer El A-responsiveness to a heterologous
promoter (24). To further elucidate the mechanism of PCNA
induction by the E1A 243R oncoprotein, we have identified
cellular transcription factors that associate with the ElA-responsive
element of the PCNA promoter (PERE). Our studies demonstrate
that ATF-1 and the hepatitis B virus enhancer-associated protein
RFX1, also known as enhancer factor C (25), interact indepen-
dently with the PERE. Furthermore, results from an expanded
analysis of the -87 to +62 region of the PCNA promoter provide
evidence that the transcription factor YY1 associates with the
initiator element of the PCNA promoter. The identification of the
transcription factor complexes reported here provides informa-
tion essential to understanding the mechanisms of regulation of
PCNA promoter activity.
MATERIALS AND METHODS
Preparation of nuclear extracts
Spinner cultures of HeLa cells (ATCC CCL2) were grown in
Dulbecco's modified Eagle's medium supplemented with 10%
fetal calf serum and 100 (Xg of penicillin and streptomycin per ml.
Human 293 cells were grown in the same medium containing 10%
calf serum instead of 10% fetal calf serum. Nuclear extracts were
prepared using a modification of the Dignam procedure (26). In
brief, cells were harvested, rinsed with ice-cold phosphate-buffered
saline and homogenized in two packed-cell volumes of Buffer A
[10 mM A'-2-hydroxyethylpiperazine-A''-2-ethanesuhconic acid
(HEPES; pH 7.9), 10 mM KC1, 1.5 mM MgCl2, 0.5 mM
dithiofhreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF)]. Nuclei were pelleted by centrifugation and homogenized
in 2.5 ml Buffer C per 109 cells [Buffer C: 20 mM HEPES, pH 7.9,
0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5
mM PMSF and 25% (v/v) glycerol]. The resulting supernatants
were dialyzed against Buffer D [20 mM HEPES, pH 7.9, 0.1 M
KC1,0.2 mM EDTA, 0.5 mM each DTT and PMSF and 20% (v/v)
glycerol], quick-frozen in liquid nitrogen and stored at -70°C.
Oligonucleotides
The wild-type PERE oligonucleotide contains sequences -60 to
-40 relative to the transcription start site of the human PCNA
promoter while the BAM oligonucleotide harbors a 4 bp mutation
(underlined) within the core of the ATF consensus binding site.
Oligonucleotide 4441 harbors a 4 bp mutation between nucleo-
tides^+4 and-^1:
PERE 5'-CAGCGTGGTGACGTCGCAACG-3'
BAM 5'-CAGCGTGGTGGAlCCGCAACG-3'
4441 5'-CAGCGTGGTGACGTCGATCGG-3'
The EP oligonucleotide corresponding to nucleotides
1151-1169 of the hepatitis B virus enhancer (5'-GATCCGTT-
GCTCGGCAACGGCCTA-3') was supplied by Y. Shaul. The
INIT oligonucleotide used for the study of the PCNA promoter-
initiator binding proteins contains sequences from -9 to +12
relative to the transcription start site of the human PCNA
promoter while mINIT harbors a CA to GT substitution
(underlined) at positions -1 and +1:
INIT 5'-CGCGGCGGCATTAAACGGTTG-3'
mINIT 5'-CCCGGCGGGXrrAAACGGTTG-3'
The oligonucleotides AAV P5 and ML TATA contain binding
sites for the transcription factors YY1 and TBP corresponding to
the adeno-associated virus P5 promoter -60 element (27) and the
adenovirus major-late promoter TATA-box (underlined) respect-
ively:
AAV P5 5'-AAGGGGGGCAAAAJGTCGGGGTGG-3'
MLTATA 5'-AAGGGGGGCTATAAAAGGGGGTGG-3'
All of the oligonucleotides contain a 5' overhang (5'-GATC-3')
for labeling. Double-stranded oligonucleotides were prepared by
annealing complementary oligonucleotides in Oligo Buffer [OB:
10 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA].
DNA probes
Oligonucleotides used as probes in electrophoretic mobility shift
assays (EMSA) were labeled with [cc-32P]dATP (3000 Ci/mmol)
and three cold NTPs using DNA polymerase I (Klenow
fragment). Proliferating cell nuclear antigen promoter fragments
(-150 bp) used as EMSA probes were released from PCNA-87
CAT plasmids (23) by £coRI and Hindlll digestion and labeled.
All probes were purified on native 6% polyacrylamide gels,
eluted from gel slices in OB containing 0.5% (w/v) SDS and
resuspended in OB following phenol extraction and precipitation.
EMSA
DNA binding assays were performed in 1 x EMSA buffer
consisting of 12 mM HEPES pH 7.6, 50 mM NaCl, 1 mM DTT
and 5% (v/v) glycerol. Oligonucleotide probes (20 000 c.p.m.)
were added to 20 \i\ binding reactions containing 5 j_ig of nuclear
extract protein and 2 \ig poly(dI-dC)-poly(dI-dC). Experiments
conducted with Schneider cell extracts used 100 ng of poly(dC-
dG) competitor DNA in the binding reactions (Fig. 8). Unless
indicated otherwise, incubations were conducted at 25-37°C for
15 min following a 15 min preincubation at the same temperature
in the absence of probe. Binding to EH87 probes was performed
under similar conditions except that 1.5 (ig of competitor DNA
was used and incubation was at 16°C. Where indicated, unlabeled
competitor oligonucleotides were added to the binding reactions
at the same time as the labeled probes, in which case an equivalent
volume of OB was added to control assays. Antibodies were
added to the binding reactions at least 1 h prior to the addition of
probe and incubation was at 4°C. Oligonucleotide-associated
complexes were resolved on 0.4-1 mm-thick 5% polyacrylamide
(29:1 Bis)-0.5 x TBE gels. Optimal resolution of EH87-asso-
ciated complexes was obtained on 1.5 mm-thick 4.5% polyacryl-
amide (39:1 Bis)-0.25 x TBE gels. Gels were run in the cold
room at 10 V/cm without buffer recirculation, fixed in 10%
methanol/10% acetic acid, dried and exposed at -70°C with
intensifying screens. Gel shift experiments with IMT and mINIT
probes were run at room temperature instead of in the cold room.
Antibodies
Rabbit antibodies raised against a full-length GST fusion protein
of ATF-1 (amino acids 57-271) and the sheep antiserum raised
against a GST-fusion protein containing amino acids 1-30 of
ATF-1 (28) were provided by S. Wagner and M. R. Green.
Transcruz® supershift antibodies against ATF-1 (C41-5.1),
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ATF-2 (F2BR-1), ATF-3 (C-19), CREB-1 (24HB4), CREB-2
(C-20) and YY1 (C-20) were purchased from Santa Cruz
Biotechnology. Anti-RFXl/EF-C serum was provided by P.
Hearing. The anti-YYl Ig3-1 antibody (29) was provided by S.
Natesan. Antibody against c-abl was provided by Y. Shaul.
In vitro transcription and translation
Plasmids for in vitm transcription-translation were provided by S.
Wagner (ATF-1) and W. Reith and P. Hearing (RFX1). RNA
encoding ATF-1 was synthesized from Sspl-unearized
pGEM3-ATF-1 (28) as described (30) and translated in a reticulo-
cyte lysate. RFX1 RNA was transcribed from ///raffll-linearized
pHRFXl (25) and translated in a reticulocyte lysate. Binding assays
with unlabeled proteins were performed immediately following
translation of ATF-1 and RFX1 synthesis reactions. 35S-methio-
nine-labeled proteins were synthesized in parallel reactions and the
translation products analyzed in 12% polyacrylamide-SDS gels.
RESULTS
Transcription factor binding sites in the minimal
ElA-responsive PCNA promoter
To understand how El A 243R induces PCNA expression, we
sought to identify the cellular transcription factors that associate
with the minimal ElA-responsive PCNA promoter which is
comprised of sequences between -87 and +62 relative to the
transcription initiation site (18). Within this region lies the PCNA
ElA-responsive element (PERE; nucleotides -59 to —45), which
harbors a putative ATF binding site, as well as a putative initiator
element and a degenerate TATA box (5'-TGAGA-3'). To identify
proteins that associate with the minimal ElA-responsive PCNA
promoter, HeLa cell nuclear proteins were incubated with probe
EH87 which comprises nucleotides from -87 to +62 of the human
PCNA promoter (Fig. 1 A, lane 1).
HeLa nuclear extracts formed five major complexes with
EH87, identified EH1 to EH5 in order of increasing mobility.
Similar complexes were also observed in adenovirus-trans-
formed human 293 cells (data not shown). We then performed
competition experiments using unlabeled double-stranded oligo-
nucleotides to determine which of these complexes contained
transcription factors that we suspected might be involved in the
regulation of PCNA promoter activity. Note that the double-
stranded PERE oligonucleotide used in the binding assays
described throughout the text also contains the sequence
5'-CAACG-3' (nucleotides -44 to -40) in addition to the PCNA
ElA-responsive element proper (nucleotides -59 to -45). Com-
plexes EH1 and EH4 were efficiently suppressed by the PERE
oligonucleotide, indicating that the proteins present in these
complexes interacted with sequences in the PCNA promoter
situated between -60 and -4-0. The experiment was repeated
using the BAM oligonucleotide which harbors a 4 bp mutation at
the core of the ATF consensus sequence that abrogates transac-
tivation of the human PCNA promoter by El A 243R in transient
expression assays in vivo (18). The BAM oligonucleotide
efficiently competed for complex EH 1 but did not affect EH4
(lane 3), strongly suggesting that the PERE-binding activity
required for PCNA promoter activation by El A resides in
complex EH4. Complex EH3, which was mildly affected by both
the PERE and BAM oligonucleotides, will not be discussed
further since we have yet to identify EH3-associated proteins.
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Figure 1. Association of cellular transcription factors with the minimal
ElA-responsive promoter and identification of PERE-associated complexes.
(A) An end-labeled PCNA promoter fragment from -87 to +62 relative to the
transcription initiation site (EH87) was incubated with 5 |ig HeLa nuclear
extract and the protein—DNA complexes resolved on a 4.5% native polyacryl-
amide gel. The major probe-associated complexes observed in lane 1 are
labeled EH1-EH5 in order of increasing mobility. Oligonucleotide competi-
tions (lanes 2-5) were performed with 5 pmol unlabeled double-stranded
oligonucleotides corresponding to the PERE, a mutated PERE (BAM), a
TBP-binding site (MLTATA) or a YY1-binding site (AAV P5). (B) Probes
derived from the wild-type PCNA-87 CAT construct (EH87) or from promoter
constructs harboring mutations in the PERE (ATF-BAM, -46/-39), putative
TATA element (-211-20) or the putative initiator element (Init-Bgl), were
incubated with HeLa nuclear extract and the protein-DNA complexes resolved
on a native gel. Complex EH6 corresponds to a novel Init-Bgl-associated
complex.
We obtained preliminary evidence for the association of other
transcription factors with the PCNA promoter. The MLTATA and
AAV P5 oligonucleotides harbor sites derived from the adenovi-
rus major late (MLTATA) and the adeno-associated virus P5
promoters (AAV P5) which bind the general transcription factor
TBP and the initiator binding protein YY1, respectively. Com-
plexes EH2 and EH5 were specifically abrogated by MLTATA
and AAV P5 respectively (lanes 4 and 5). These results imply the
association of a TATA box-binding complex (EH2) and a
complex containing the transcription factor YY1 (EH5) with the
PCNA promoter. It is noteworthy that complexes EHI, EH3 and
EH4 were not significantly affected by the MLTATA and AAV P5
competitor oligos. Thus, the formation of each of the five major
EH complexes was affected by at least one competitor oligo-
nucleotide.
To localize the regulatory elements corresponding to com-
plexes EH1-EH5, we performed gel retardation assays employ-
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ing EH87 probes with mutations derived from PCNA-CAT
linker-scanning constructs (23). In agreement with the competi-
tion assays, the ATF-BAM probe derived from this construct
failed to form complex EH4 (Fig. IB, lane 2). However, despite
its abrogation by a competing BAM oligonucleotide (Fig. 1A),
complex EH1 did not associate with the BAM probe. A possible
explanation would be that the BAM mutation is deleterious for
binding of proteins to the ATF site and to a possible adjoining site
but that proteins may still bind to this second element at the high
concentrations of oligonucleotide used in the competition assays.
Mutation of nucleotides -46 to -39 (EH4639) reduced EH1
formation without affecting complex EH4. Since this mutation
permits wild-type activity of the PCNA promoter in transfection
experiments (23), these data also point to EH4 as the relevant
complex as far as induction by El A 243R is concerned (lane 3).
A mutation in the region of the putative initiator element
(EHINTT-Bgl) caused a decrease in the intensity of complex EH5
and the appearance of a new complex, EH6 (lane 5), suggesting
that this is a site for the binding of transcription factor YY1. In
support of these results, the INIT-Bgl mutation disrupts a
consensus YY1 binding site (5'-CATT-3') located from -1 to +3 of
the PCNA promoter. On the other hand, although the competition
experiments suggested the association of a TATA-box binding
complex on the PCNA promoter (Fig. 1A, lane 4), a probe
containing a BgUl linker substitution from -27 to -20 (EH2720)
which disrupts the putative TATA element did not adversely affect
EH2 formation (lane 4). Mobility shift assays employing mutant
probes derived from other PCNA-CAT linker-scanning constructs
also failed to localize complex EH2 (data not shown). The
characterization and mapping of complex EH2 remains to be
determined.
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Defining PERE-associated complexes
To examine PERE-binding complexes more specifically, HeLa cell
nuclear extracts were incubated with the PERE oligonucleotide
(Fig. 2A). We detected three major PERE-binding activities in
HeLa cells labeled PI, P2 and P3. Two of these, P2 and P3, appear
to be specific for ATF-binding since they were unaffected by
competition with the BAM oligonucleotide (lane 5) but disap-
peared upon addition of PERE (lane 4). The formation of
complexes P2 and P3 was relatively temperature-independent
whereas complex PI was sensitive to elevated temperatures (Fig.
2B). In fact, appreciable amounts of P2 and P3 were observed
when binding reactions were incubated at 75 °C prior to the
addition of probe, while PI, on the other hand, was sensitive to
temperatures as low as 55 °C. Similar experiments conducted with
EH87 probe and with fractionated HeLa nuclear extracts (data not
shown) lead us to believe that PI corresponds to at least part of the
binding activity in EH1, while P2 and P3 correspond to EH4.
ATF-1 associates with the PERE
The presence of an ATF site in the PERE suggested that one or
several members of the ATF transcription factor superfamily might
associate with the PCNA promoter. In addition, the heat-stability
of complexes P2 and P3 was consistent with the possibility that
ATF-1 is a component of these complexes (31). To test this
hypothesis, PERE-binding assays with HeLa nuclear extracts were
conducted in the presence of three different antibodies raised
against ATF-1. As shown in Figure 3, both complexes P2 and P3,
Figure 2. PERE-associated complexes. (A) Radiolabeled PERE oligonucleo-
tide corresponding to nucleotides -60 to -40 relative to the transcription start
site of the human PCNA promoter was incubated with 5 p.g HeLa cell nuclear
extract at 4°C, room temperature (RT) or 37°C and the protein-DNA
complexes resolved on a native 5% polyacrylamide gel. Three major
complexes, denoted PI, P2 and P3 are identified. Incubations at 37°C were
performed in the absence (lane 4) or presence of 5 pmol unlabeled PERE or
BAM oligonucleotides (lanes 4 and 5) (Note that PI migrates -1 cm into the
gel). (B) To determine the heat-sensitivity of PERE-protein interactions,
binding reactions were incubated at temperatures ranging from 37 to 75°C
preceding the addition of labeled PERE probe.
but not complex PI, were supershifted by a mouse monoclonal
antibody raised against ATF-1 (lane 2). Similar results were
obtained with a rabbit polyelonal antibody raised against aiiiinu
acids 57-271 of ATF-1 (lane 3). Since ATF-1 shares 64% amino
acid identity with CREB-1, we also tested a sheep polyelonal
antibody raised against the first 30 amino acids of ATF-1 expressed
as a glutathione-S-transferase-ATF-1 fusion protein (28). This
antibody does not react with CREB-1, but it also supershifted
complexes P2 and P3 (lane 4) whereas a preimmune serum did not
(lane 5). Together these results indicate that ATF-1 is a major
component of PERE-associated complexes P2 and P3. As shown
below, CREB-1 does not appear to be contained in these
complexes.
As an additional proof of ATF-1 binding to the PERE, we
examined the PERE-binding ability of ATF-1 synthesized in vitro
in a rabbit reticulocyte lysate (Fig. 4). Several PERE-associated
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Figure 3. ATF-1 is a major component of complexes P2 and P3. Labeled PERE
probe was incubated with HeLa cell extracts and the protein-DNA complexes
analyzed by gel retardation assay as in Figure 2. Extracts were incubated in the
absence (lane 1) or presence (lanes 2-4) of antibodies to the transcription factor
ATF-1:C41-5.1 (100 ng),a-57-271 (1 ul of a 1/5 dilution) and a-1-30(1 ul)
C41-5.1 is a mouse monoclonal antibody while a-57-271 and ct-1-30 are
polyclonal rabbit and sheep antibodies respectively, raised against the
corresponding amino acids of ATF-1 expressed as GST-fusion proteins. As a
control, nuclear extract was incubated with normal sheep serum (lane 5) A
schematic diagram of ATF-1 is shown below for reference. The basic region
(amino acids 210-240) and the leucine zipper (amino acids 241-271) of ATF-1
are indicated.
Figure 4. In vi>ro-translated ATF-1 binds to PERE. Full-length ATF-1 was
synthesized in vitro (IVT-ATF-1) and incubated with oc32P-labeled PERE probe.
IVT-ATF-1 formed a specific complex, < (lane 5), which migrated in the vicinity
of complexes P2 and P3 observed in HeLa nuclear extract (lane 1). Lane 2, HeLa
nuclear extract and reticulocyte lysate; lane 3, BSA alone (5 ug of Boehringer
Manheim BSA was present in all binding reactions containing reticulocyte
lysate); lane 4, BSA and reticulocyte lysate; lanes 5-8, programmed reticulocyte
lysate alone or in the presence of unlabeled competitor PERE (lane 6), BAM
oligonucleotide (lane 7) or and-ATF-1 antibody (lane 8).
complexes were formed with unprogrammed reticulocyte lysate
(lane 4). Although these complexes were specifically competed
by PERE oligonucleotide (lane 6), they migrated faster than
complexes P2 and P3 and were unaffected by an antibody against
ATF-1 (lane 8). On the other hand, reticulocyte lysate programmed
with transcript of the full-length ATF-1 cDNA formed a single
protein-DNA complex migrating in the vicinity of complex P3
(lane 5). The specificity of the PERE-ATF-1 interaction was
confirmed by oligonucleotide competition with the BAM oligo
(lane 7) and coincubation with an anti-ATF-1 antibody (lane 8). It
is tempting to speculate that the homodimer observed in reticulo-
cyte lysates corresponds to HeLa P3 complex, but more definitive
experiments will be required to determine if other proteins are
present in complexes P2 and P3 or if these complexes reflect
post-translational modifications of ATF-1 such as phosphorylation.
ATF-1 binding proteins
ATF transcription factors bind DNA as heterodimers or homo-
dimers (30). To date, ATF-1 has been shown to dimerize with
itself or with CREB-1 (28,32). However, while complexes P2 and
P3 could be supershifted by as little as 25 ng of monoclonal
antibody against ATF-1 (Fig. 3), up to 1 |Xg of monoclonal
antibody raised against CREB-1 failed to disrupt either complex
(Fig. 5A, lane 2). Similar results were obtained with antibodies
raised against several other members of the ATF family, including
ATF-2 and CREB-2 (lanes 1 and 3), as well as ATF-3, Jun and Fos
(data not shown). To confirm our findings in another cell line we
performed gel shift assays with nuclear extract from adenovirus-
transformed 293 cells. The similar gel shift pattern obtained with
293 cell extract indicated that the adenovirus El proteins, present
at high levels in 293 cells, do not greatly influence the complexes
detected. In agreement with results obtained in HeLa cells, only
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Figure 5. PERE-binding proteins in HeLa and 293 cells. (A) Radiolabeled
PERE probe was incubated with 5 |ig HeLa cell nuclear extract and the resulting
protein-DNA complexes analyzed by gel retardation assay. Extracts were
incubated at 4°C with 1 ug of antibodies to the ATF-2, CREB-1 and CREB-2
transcription factors prior to addition of the probe (lanes 1-3, respectively) (B)
5 |lg of 293 nuclear extract was incubated with PERE probe and the resulting
complexes resolved on a native 5% polyacrylamide gel. Complexes P1-P3 are
identified. 293 extract was incubated in the absence (lane I) or presence (lanes
2-6) of monoclonal or purified polyclonal antibodies to the transcription factors
ATF-1, ATF-2, ATM, CREB-1 and CREB-2. 25 ng of anti-ATF-1 antibody
was used in lane 2 while 1 (ig of the indicated antibodies were used in lanes 3-6.
ATF-1 could be detected in PERE-associated complexes in 293
cells (Fig. 5B). None of the antibodies affected PI. While it is
possible that the antibodies used do not recognize their cognate
proteins under the assay conditions used, the experiments
described above clearly identify ATF-1 as the major component
of PERE-associated complexes.
Enhancer factor C (RFX1) binds to the PERE
Since the PERE oligonucleotide-associated PI complex was
sensitive to competition by both the PERE and BAM oligo-
nucleotides (Fig. 2), we considered the possibility that this
oligonucleotide, which encompasses the region from -60 to -40
of the PCNA promoter contains a second element distinct from
the ATF site. The sequence 5'-GCAACG-3' located between
nucleotides -45 and —40 corresponds to one of two repeats found
in the hepatitis B virus enhancer EP element (33). Addition of
unlabeled EP oligonucleotide to PERE-binding assays effectively
eliminated complex PI (Fig. 6, lane 4) but PI was unaffected by
coincubation with a mutated EP oligonucleotide (data not shown)
and was reduced but not abolished with a PERE oligonucleotide
harboring a 4 bp mutation between —44 and -41 (oligonucleotide
4441, lane 3). These results raised the possibility that the c-abl
tyrosine kinase, which has been shown to bind to the HBV EP
element and whose activity is regulated by the retinoblastoma
protein (34,35), might associate with the human PCNA promoter.
However, three different antibodies raised against c-abl failed to
specifically affect complex PI (data not shown). On the other
hand, an antiserum against enhancer factor-C (EF-C), which also
interacts with the HBV EP element (36), specifically supershifted
complex PI (lane 5), strongly suggesting that EF-C might
associate with the PERE probe. The specificity of the supershift
by anti-EF-C antibody was confirmed by the resistance of the PI
complex to normal rabbit serum and an anti-YYl antibody (C-20)
(lanes 6 and 7). To substantiate the importance of the
5'-GCAACG-3' repeat between nucleotides -45 and -40 for
complex PI formation we incubated HeLa cell nuclear extract
with radiolabeled 4441 probe in place of wild type PERE probe.
Significantly, the 4441 probe formed complexes P2 and P3, but
not PI (lane 8).
The results of the antibody supershift experiment were
confirmed by examining the PERE-binding ability of in vitro-
synthesized (IVT) EF-C (Fig. 7). EF-C is identical to the major
histocompatibility complex class II regulatory factor RFX1 (25).
Reticulocyte lysate programmed with the full-length RFX1
cDNA formed a PERE-associated complex that migrated in the
vicinity of complex PI (lane 3). A faster migrating PERE-asso-
ciated complex was observed in the unprogrammed reticulocyte
lysate (lane 2). Although formation of this complex was reduced
by the PERE and 4441 oligonucleotides (lanes 4 and 5), it was not
affected by the EP oligonucleotide or any of the antibodies tested.
In contrast, the IVT-RFX1 complex disappeared upon addition of
PERE or EP oligonucleotide but was not eliminated by coincuba-
tion with oligonucleotide 4441 (lanes 4—6). Moreover, the
PERE-associated complex formed in the presence of IVT-RFX1
was specifically supershifted by the addition of anti-RFXl
antiserum but was unaffected by preimmune rabbit serum or an
unrelated antibody (anti-ATF-1) (lanes 7-9). In accordance with
these results, IVT-RFX 1 did not associate with labeled 4441
oligonucleotide (lane 10) but did form a complex with labeled EP
probe (lane 11).
YY1 protein associates with the initiator element of the
PCNA promoter
The transcription factor YY1 has been shown to bind to the
initiator element and mediate transactivation by El A (27,29).
The observation that an oligonucleotide corresponding to the
YYl-binding site situated at -60 in the AAV P5 promoter can
compete for one of the PCNA promoter-associated complexes
(Fig. 1), raised the possibility that YY1 interacts with PCNA
promoter elements. Furthermore, our results with the EH
INIT-Bgl probe (Fig. IB, lane 5) suggested that the binding site
for YY1 on the PCNA promoter resides between nucleotides -1
to +3 with respect to the transcription initiation site. To determine
whether YY1 binds to the initiator element of the PCNA
promoter, we performed binding assays using a double-stranded
oligonucleotide probe comprised of nucleotides -9 to+12 relative
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Figure 6. RFX1 is a major component of the PI complex. HeLa cell nuclear
extract (5 ng) was incubated with radiolabeled PERE probe (lanes 1-8) and the
resulting protein-DNA complexes analyzed by gel retardation assay. Com-
plexes PI, P2, and P3 are denoted. Extract was incubated in the absence (lane
1) or presence of excess unlabeled competitor oligonucleotides PERE (lane 2),
4441 (lane 3) or EP (lane 4) As shown below, oligonucleotide 4441 contains a
4 bp mutation in nucleotides -44 to -41 of the PERE oligonucleotide
(5'-ATCG-3' instead of 5'-CAAC-3') which disrupts the putative RFX1-bind-
ing site contained within the PERE. EP corresponds to an RFX1 binding site
present in the hepatitis B virus enhancer. In lanes 5-7, nuclear extract was
preincubated with antiserum raised against RFX1 (lane 5), normal rabbit serum
(NRS, lane 6) or an antibody against YYl (lane 7) A supershifted RFX1
complex observed in the presence of anti-RFXl antiserum is denoted by a
> (lane 5). As a control, HeLa extract was incubated with labeled 4441
oligonucleotide (lane 8).
Figure 7. In vi'rro-synthesized RFX1 binds to the PERE. RFX1 was synthesized
in vitro (P/T) using a reticulocyte lysate programmed with mRNA generated
from linearized pHRFX-1 plasmid. Incubation of IVT-RFXI with radiolabeled
PERE probe (lane 3) resulted in the formation of a specific complex that
co-migrated with complex PI observed in HeLa cell nuclear extract (lane l).The
unlabeled competitor oligonucleotides PERE, 4441 and EP were added to
binding reactions containing IVT-RFX1 (lanes 4-6), while antiserum to RFX1,
normal rabbit serum (NRS) or monoclonal antibody to ATF-1 were added in
lanes 7-9. A supershifted complex, is denoted in lane 4. As controls,
radiolabeled 4441 (lane 10) and EP (lane 11) oligonucleotides were incubated
with IVT-RFXI. As in Figure 5, 5 |ig of BSA was present in the binding
reactions shown in lanes 2—11. The unmarked bands in lane 1 were observed
due to the longer exposure time required for detection of the IVT-RFX 1 -PERE
complex.
to the site of transcription initiation (INIT). As illustrated in
Figure 8, incubation of INIT with HeLa nuclear extracts gave rise
to two retarded complexes referred to as YS and YF (YYl slow
and YYl fast). Oligonucleotide competition experiments with the
AAV P5 (-60) oligo abrogated YF formation and reduced YS
formation (lane 4). Furthermore, complexes YS and YF disap-
peared upon addition of the INIT oligonucleotide (lane 5). In
addition, neither complex was detected when nuclear extracts
were incubated with a probe (mlNIT) harboring a CA to GT
mutation at positions — 1 and +1 (lane 6), nor did the mutated
oligonucleotide compete for wild-type INIT associated YS and
YF complexes (data not shown). Together these results establish
that YS and YF result from specific interactions with the PCNA
promoter initiator element.
Antibody interference experiments demonstrated that YYl is
present in both complexes associated with the PCNA promoter
initiator. YF was disrupted by coincubation with a commercially
available polyclonal antibody (lane 2), as well as by anti-YYl
Ig3-1 (lane 4), a monoclonal antibody that has been shown to
disrupt, rather than supershift, YYl-containing complexes
(29,37). On the other hand, the YS complex was disrupted, by
anti-YYl Ig3-1, but not by the polyclonal antibody. This result
suggests that the epitope recognized by the polyclonal antibody,
namely amino acids 395—414, is inaccessible in complex YS. To
confirm that YYl binds to the PCNA promoter initiator, we
incubated INIT oligonucleotide with extracts prepared from
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Figure 9. Structure and activation of the human PCNA promoter. Arrows
indicate possible sites for regulation of PCNA promoter-associated transcrip-
tion factors by El A 243R. The PCNA E1A 243R-responsive element (PERE,
boxed) is comprised of nucleotides from -59 to -45 relative to the transcription
initiation site. Nucleotides -44 to -40 which bear homology to the hepatitis B
virus enhancer RFX1 binding site. The PERE oligonucleotide used in the
binding assays contains both elements. ATF-1 and RFX1 bind to overlapping
sites contained within the PERE. Co-occupancy of the PERE by both ATF-1
and RFX1 is shown for illustrative purposes only, since these proteins are
present in distinct PERE-associated complexes. Mutations between -50 and
-41 abolish RFX1 binding (BAM and 4441 mutations), while nucleotides -53
to -47 are critical for ATF-1 binding (BAM mutation and unpublished
observations). In addition, the transcnption factor YYI binds to the initiator
element of the human PCNA promoter. The consensus YYI binding site is
boxed and the CA dinucleotide required for YYI binding (muNrT mutation) is
bracketed. GTFs: general transcription factors.
Figure 8. Transcription factor YY1 associates with the initiator element of the
human PCNA promoter. Two complexes, identified as YS (YYI slow) and YF
(YYI fast) on the basis of their relative mobilities, were observed upon
incubation of HeLa cell nuclear extract (5 |xg) with a radiolabeled double-
stranded oligonucleotide (INIT) composed of nucleotides from -9 to +12
relative to the transcnption initiation site of the human PCNA promoter (lane
1). Additional binding reactions contained monoclonal antibodies to YYI
(lanes 2 and 3) or excess competitor oligonucleotides corresponding to a known
Y Y1 binding site (AAV P5 oligo) (lane 4) or wild type PCNA promoter initiator
element (INIT) (lane 5). As a negative control, the mINIT oligonucleotide was
used as probe (lane 6). The sequences of the INIT and mINIT oligonucleotides
(sense strand only) are shown at the bottom of the figure. The mINIT
oligonucleotide contains a CA to GT mutation at positions -1 and +1. In lanes
7 and 8, the INIT probe was incubated with extracts prepared from Schneider
cells (lane 7) or from Schneider cells transfected with a YY 1-expressing
plasmid (lane 8). An INIT-binding complex observed in YY 1-expressing
Schneider cells is identified (Y).
Drosophila Schneider SL2 cells, which lack detectable YYI (29)
(lane 7), as well as with extracts prepared from YYI-expressing
Schneider cells (lane 8). INIT-binding activity was observed only
with the YYI-expressing Schneider cell extract, thus reproducing
the results observed with HeLa nuclear extracts. In contrast to
HeLa cells, however, Schneider cell YYI formed a single
complex Y which migrated between HeLa cell YS and YF,
implying that an additional factor (or factors) present in HeLa
cells but absent from Schneider cell extract can form an additional
complex with YYI.
DISCUSSION
We have characterized cellular transcription factors that associate
with the adenovirus-responsive human PCNA promoter to gain
further insight into the molecular mechanism of transcriptional
activation by the El A 243R oncoprotein and its relation to the
transformation process (Fig. 9). We previously showed that the
PCNA ElA-responsive element (PERE) which is required for
induction of PCNA by El A 243R and confers ElA-responsive-
ness onto a heterologous promoter in vivo is comprised of
nucleotides -59 to -45 relative to the transcription initiation site
(23,24). The activating transcription factor-1 (ATF-1) was shown
to interact with the ATF binding site of the ElA-responsive
element of the human PCNA promoter (PERE) and appears to
constitute a major component of PERE-associated complexes
required for PCNA induction by El A 243R. The identification of
enhancer factor C (EF-C/RFX1) in association with an element
overlapping the 3' end of the PERE contributes a new participant
to the regulation of PCNA promoter activity. Moreover, the
demonstration that YYI binds to the initiator element of the
PCNA promoter implicates an additional player in the regulation
of expression from TATA-less promoters. Finally, the identifica-
tion of a complex competed by the MLTATA oligo on the PCNA
promoter suggests that general transcription factors such as TBP
play a role in regulating transcriptional expression of PCNA.
The role of EF-C/RFX1 in the regulation of PCNA promoter
activity is unknown at the present time. RFX1 transactivates the
HBV enhancer and is required for MHC class II gene expression
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(25,38). However, RFXl binding appears dispensable for PCNA
activation by ElA 243R in HeLa cells since a promoter construct
containing a mutation in the RFXl binding site is efficiently
activated by ElA 243R (23). The possibility that RFXl plays an
essential role in PCNA expression in HeLa cells cannot be ruled
out, however, as mechanisms can be envisaged in which RFXl
would associate with the PCNA promoter without binding to
DNA sequences, perhaps via protein-protein interactions. Fur-
thermore, RFXl may play a more crucial role in PCNA activity
in cell types other than HeLa cells. It is of interest to note that
RFXl and ATF-1 are present in different PERE-associated
complexes, PI and P2-P3, respectively. This might imply that
they do not co-occupy the PERE and thus may exert opposite
effects on PCNA promoter activity. An alternative and equally
attractive explanation would be that ATF-1 and RFXl may serve
to relay different intracellular signals to the human PCNA
promoter. In contrast to the human PCNA promoter, the
PERE-RFXl-binding element (5'-GCAACG-3') is not found in
murine promoter sequences near the ATF-CRE consensus site
(39), suggesting that this element is dispensable or else confers an
additional regulatory mechanism upon the human PCNA pro-
moter. As a further difference, the murine promoter contains
putative binding sites for the transcription factors PEA3 and E2F
(40,41).
There is no doubt, however, as to the important functional role
of the ATF-CRE site present in the human and murine PCNA
promoters. The ability of ElA 243R to transactivate PCNA
promoter constructs in transient expression assays correlates with
the presence of PERE-associated complexes P2 and P3, which
contain the ATF-1 protein. Moreover, increased binding of
nuclear proteins to a human PCNA promoter probe encompass-
ing the PERE (-68 to -36) is observed upon growth stimulation
of Syrian hamster fibroblasts (40). In addition, the ATF-CRE
motif present in the murine promoter binds ATF-1 and contributes
to the inducibility of the mouse PCNA promoter by interleukin-2
(41). The association of ATF-1 with critical regulatory elements
in both the human and murine PCNA promoters indicates that this
transcription factor may lie at the convergence of multiple
transcriptional regulatory pathways. ATF-1 has been shown to
mediate cAMP- and calcium-dependent transcriptional regula-
tion, in some instances as efficiently as CREB (28,42). However,
despite the association of ATF-1 with the adenovirus El A-induc-
ible human PCNA promoter and the Tax-dependent human T-cell
leukemia virus 1 (HTLV-1) enhancer (43), GAL4-ATF-1 fusion
proteins have been notoriously refractory to activation by viral
transactivators such as ElA or Tax (44,45), suggesting that a
protein that associates with ATF-1 may in fact constitute a target
for ElA. We have shown that ATF-1 is present in two
PERE-associated complexes, P2 and P3, therefore allowing for
the formation of ATF-1 homodimers and heterodimers. Although
other unknown proteins may dimerize with ATF-1, CREB is the
only member of the ATF transcription factor family known to
form heterodimers with ATF-1 (28,32,42). However, as a GAL4
fusion protein, CREB is only weakly activated by El A (44) and
we have not detected CREB in PERE-associated complexes. It
should also be noted that while the PCNA promoter-associated
complexes EH4, P2 and P3 clearly contain ATF-1, complexes
EH 1 and P1, which are at least partly ATF-site dependent, contain
protein(s) that do not react with antibody to ATF-1. In fact, the
deleterious effect of the BAM mutation on the binding of RFX-1
to the EH 87 probe suggests that EH1 may in fact constitute a
multi-protein complex (Fig. 1). The nature and significance of
this complex remains to be established.
We have used other immunological reagents to identify
candidate PERE-binding proteins. ATF-2 has recently been
implicated in the induction of the human c-jun gene by 243R (46).
Neither ATF-2, the first ATF family member shown to mediate
transcription activation by E1A 289R (45,47), nor CREB2, which
is also El A 289R-responsive (44), appeared to associate with the
PERE. Moreover, no association was detected between ATF-2
and a -46/-39 PCNA promoter construct in which the ATF site
was converted to a perfect palindrome (5'-TGACGTCA-3'),
suggesting that discrete PERE nucleotides may dictate specific
protein-DNA interactions (unpublished observations). Addi-
tional experiments will be necessary to identify which ATF
family member(s) interact(s) with ATF-1. To this end, we have
embarked on the purification of PERE-binding proteins using
DNA affinity chromatography and have detected four proteins in
the range of 37-50 kJDa that associate with the PERE in
UV-crosslinking experiments (unpublished observations). The
identities of these proteins remain to be determined.
The existence of two PCNA promoter initiator-associated
complexes containing YY1 in HeLa cells suggests that the initiator
may also be the site of regulatory events involving protein-protein
interactions. YY1 has been shown to interact with the transcription
factors Spl and c-myc (48,49). YY1 appears to influence
transcription factor function by regulating promoter structure (37).
Moreover, YY1, along with l'HIB and RNA polymerase II, is
sufficient to direct basal transcription from a TATA-less promoter
in vitro (50). Interestingly, ElA 243R has also been shown to
relieve transcriptional repression by YY1 (27,29). However,
previous experiments using linker-scanning mutants of the human
PCNA promoter harboring substitutions or deletions within the
initiator element did not reveal a requirement for YY1 (23). As
postulated at that time, it is likely that the mutations we studied
encoded cryptic initiator elements. This impression was confirmed
by the observation that complex EH5 (and EH6) that form on the
PCNA-Init-Bgl probe are disrupted by coincubation with anti-
YY1 antibody in a DNA-binding assay (B.L., unpublished
observations). In any event, how these varied activities of YY1
relate to PCNA promoter activity will require further investigation.
Finally, it is noteworthy that none of the PCNA promoter-bind-
ing proteins identified here, namely ATF-1, RFXl or YY1, is
present in the same EH-associated complexes (Figs 1 and 9).
While this may stem from an inherent instability of higher-order
complexes in the gel systems used, it seems more likely to reflect
their lower abundance. This mutually exclusive binding may also
reflect different states of transcriptional 'alertness' of the PCNA
promoter. The identification of PCNA promoter-binding tran-
scription factors and their respective binding sites will allow the
detailed examination of the dynamic interrelationships between
these proteins and their respective roles in the transcriptional
activation of PCNA activity.
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